Patents by Inventor Heather Stephenson

Heather Stephenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteolytic inactivation of select proteins in bacterial extracts for improved expression
    Patent number: 11261219
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: March 1, 2022
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson
  • ANTI-PD-1 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-PD-1 ANTIBODIES AND METHODS OF USING ANTI-PD-1 ANTIBODIES
    Publication number: 20210107981
    Abstract: Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: October 12, 2020
    Publication date: April 15, 2021
    Inventors: Alice YAM, Ryan STAFFORD, Aaron SATO, John LEE, Avinash GILL, Junhao YANG, Heather STEPHENSON
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 10882907
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 5, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 10836825
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: November 17, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
  • Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
    Patent number: 10822414
    Abstract: Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: November 3, 2020
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Alice Yam, Ryan Stafford, Aaron Sato, John Lee, Avinash Gill, Junhao Yang, Heather Stephenson
  • PROTEOLYTIC INACTIVATION OF SELECT PROTEINS IN BACTERIAL EXTRACTS FOR IMPROVED EXPRESSION
    Publication number: 20200062807
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Application
    Filed: September 6, 2019
    Publication date: February 27, 2020
    Inventors: Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson
  • Proteolytic inactivation of select proteins in bacterial extracts for improved expression
    Patent number: 10450353
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: October 22, 2019
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson
  • ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES
    Publication number: 20190233512
    Abstract: The present disclosure relates to antibodies that selectively bind to folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: October 11, 2017
    Publication date: August 1, 2019
    Inventors: Ryan STAFFORD, Alice YAM, Xiaofan LI, Robert HENNINGSON, Sihong ZHOU, Heather STEPHENSON, Junhao YANG, Aaron SATO
  • MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3
    Publication number: 20180371086
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Applicant: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Joshua Goldsmith, Craig S. Pace, Derek Sloan, Heather Stephenson, Nathan D. Thomsen, George Kukolj, Doug Rehder
  • ANTI-PD-1 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-PD-1 ANTIBODIES AND METHODS OF USING ANTI-PD-1 ANTIBODIES
    Publication number: 20180142022
    Abstract: Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 24, 2018
    Applicant: SUTRO BIOPHARMA, INC.
    Inventors: Alice YAM, Ryan STAFFORD, Aaron SATO, John LEE, Avinash GILL, Junhao YANG, Heather STEPHENSON
  • PROTEOLYTIC INACTIVATION OF SELECT PROTEINS IN BACTERIAL EXTRACTS FOR IMPROVED EXPRESSION
    Publication number: 20170283469
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Application
    Filed: April 10, 2017
    Publication date: October 5, 2017
    Inventors: Christopher D. THANOS, Christopher J. MURRAY, Junhao YANG, Heather STEPHENSON
  • Proteolytic inactivation of select proteins in bacterial extracts for improved expression
    Patent number: 9650621
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 16, 2017
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson
  • PROTEOLYTIC INACTIVATION OF SELECT PROTEINS IN BACTERIAL EXTRACTS FOR IMPROVED EXPRESSION
    Publication number: 20150259664
    Abstract: The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.
    Type: Application
    Filed: October 8, 2013
    Publication date: September 17, 2015
    Inventors: Christopher D. Thanos, Christopher J. Murray, Junhao Yang, Heather Stephenson